Search

Your search keyword '"Yoshida, Hidemi"' showing total 648 results
Start Over Author "Yoshida, Hidemi"
648 results on '"Yoshida, Hidemi"'

20. Toll-Like Receptor 3 as a Recurrence Risk Factor and a Potential Molecular Therapeutic Target in Colorectal Cancer

Author

Yoshida, Tatsuya, Miura, Takuya, Matsumiya, Tomoh, Yoshida, Hidemi, Morohashi, Hajime, Sakamoto, Yoshiyuki, Kurose, Akira, Imaizumi, Tadaatsu, and Hakamada, Kenichi

Subjects
recurrence, Clinical and Experimental Gastroenterology, CCL5, IL-8, viruses, virus diseases, chemical and pharmacologic phenomena, hemic and immune systems, colorectal cancer, toll-like receptor 3, CCL2, Original Research
Abstract

Tatsuya Yoshida,1 Takuya Miura,1 Tomoh Matsumiya,2 Hidemi Yoshida,2 Hajime Morohashi,1 Yoshiyuki Sakamoto,1 Akira Kurose,3 Tadaatsu Imaizumi,2 Kenichi Hakamada1 1Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan; 2Department of Vascular Biology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan; 3Department of Anatomic Pathology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, JapanCorrespondence: Kenichi HakamadaDepartment of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, JapanTel +81 172 39 5079Fax +81 172 39 5080Email hakamada@hirosaki-u.ac.jpPurpose: Colorectal cancer (CRC) often recurs after curative resection. Identification of major risk factors for CRC recurrence is important for effective prevention and treatment. In this study, we examined the potential relationship between CRC and TLR3 as this remains unclear.Patients and Methods: Correlations between TLR3 immunostaining and clinicopathological factors and prognosis were examined in 50 samples that were randomly extracted from 264 patients with CRC from January 2010 to December 2011. Chemokines induced by TLR3 agonist stimulation were also examined using TLR3-positive human CRC cell lines. Furthermore, the association between TLR3 and chemokine expression was assessed by analyzing the immunohistochemistry of surgical specimens.Results: Of the 50 patients, 14 (28%) were TLR3-negative. In the comparison of clinicopathological factors between the TLR3-negative and -positive groups, there were more lymph node metastasis-positive cases in the TLR3-negative group, and this difference was significant. Furthermore, there was no difference in overall survival rates between the two groups, but the 5-year recurrence-free survival (RFS) was significantly lower in the TLR3-negative group (46.2%) than in the TLR3-positive group (78.1%). Analysis of 5-year RFS using factors thought to be related to recurrence identified a high tumor budding and a TLR3-negative status as independent risk factors for recurrence. TLR3 activation of CRC cell lines induced expression of C-C motif chemokine ligand 2 (CCL2), C-C motif chemokine ligand 5 (CCL5), and interleukin-8. The expressions of CCL2, CCL5, and IL-8 were observed in the TLR3-positive tumor cells of surgical specimens.Conclusion: Non-expression of TLR3 in CRC cells was associated with lymph node metastasis and was an independent risk factor for recurrence. These results suggest that TLR3 may not only be used as a prognostic factor and a risk factor for recurrence, but further studies on the involvement of TLR3 with tumor growth may provide new therapeutic strategies.Keywords: colorectal cancer, toll-like receptor 3, recurrence, CCL2, CCL5, IL-8

Published
2020

27. Effect of low-concentration amyloid-β 1–42 (Aβ42) on human neuroblastoma SH-SY5Y cell viability: neuroprotective potential of combination use with carnosic acid, rebamipide, edaravone, and resveratrol

Author

Yoshida, Hidemi, Hashimoto, Yuko, Fukushima, Takashi, Tanji, Kunikazu, Matsumiya, Tomoh, Seya, Kazuhiko, Kawaguchi, Shogo, and Imaizumi, Tadaatsu

Subjects
low-concentration Aβ42, combination treatment, Alzheimer’s disease, cell viability, SH-SY5Y cells
Abstract

Toxic amyloid-beta （Aβ） is known to generate symptoms of Alzheimer’s disease （AD）; however, less is known regarding the neurotoxicity of Aβ at lower concentrations. Moreover, the neuroprotective potential of combination treatment with plant biophenols and existing drugs is not well understood. In this study, we estimated the no-observed adverse effect level （NOAEL） of Aβ 1–42 （Aβ42） against cultured human neuroblastoma SHSY5Y cells, and examined the neuroprotective effect of combination pretreatment with 10 μM carnosic acid, 30 nM rebamipide, 10 μM edaravone, and 10 μM of resveratrol （the “CRER” blend） on weak but toxic Aβ42-treated SH-SY5Y cells. We evaluated the NOAEL of Aβ42 at 500 nM in these cells. Aβ42 at 1–8 μM reduced cell viability; however, the “CRER” blend ameliorated this Aβ42-induced decrease in viability. The “CRER” blend induced the expression of Aβ-degrading enzymes including matrix metalloproteinase-14 （MMP-14） and neprilysin, while also enhancing the expression of the inducible α-secretase TACE （tumor necrosis factor-α-converting enzyme）, sirtuin 1 （SIRT1）, and brain-derived neurotrophic factor（ BDNF）. Collectively, our results indicate that the “CRER” may aid in the prevention of Aβ toxicity by enhancing MMP-14, neprilysin, TACE, SIRT1, and BDNF. Thus, the “CRER” blend may prove to be a promising strategy for the prevention of Aβ-mediated disorders, particularly AD.

Published
2019

28. Retinoic Acid-Inducible Gene-i and CXCL10 are Involved in Biliary Atresia

Author

Kimura, Toshiro, Imaizumi, Tadaatsu, Yoshida, Tatsuya, Shimada, Taku, Hayakari, Ryo, Kawaguchi, Shogo, Yoshida, Hidemi, Kobayashi, Tamotsu, Hirabayashi, Takeshi, Mizukami, Hiroki, Kijima, Hiroshi, and Hakamada, Kenichi

Subjects
poly（I:C）, viruses, CXCL10, HuCCT1, virus diseases, chemical and pharmacologic phenomena, biliary atresia, biological phenomena, cell phenomena, and immunity, biochemical phenomena, metabolism, and nutrition, retinoic acid-inducible gene-I
Abstract

Purpose: Retinoic acid-inducible gene-I （RIG-I） is a member of cytoplasmic viral sensors which plays an important role in inflammation of biliary epithelial cells（ BECs）. The aim of this study is to examine if RIG-I and C-X-C motif chemokine 10（ CXCL10） are involved in the etiology of human biliary atresia（ BA）. Methods: Immunohistochemical study was performed on surgically resected tissues obtained（ June 1994 to March 2016）from 30 infants with BA and non-inflamed hepatic tissues from 7 infants with hepatoblastoma. A semiquantitative scoring system was designed to evaluate the staining with an antibodies to the RIG-I and CXCL10. The expression of RIG-I and CXCL10 in HuCCT1 cholangiocarcinoma cell line were studied by western blotting, ELISA and RT-PCR analyses. Results: Intense immunoreactivity for RIG-I and CXCL10 was detected in BECs in tissues resected from BA patients.The expression of RIG-I and CXCL10 in the hilar tissue was significantly stronger than in the hepatic tissue.Transfection of HuCCT1 cells with poly（I:C）, a synthetic analog of viral dsRNA, induced the expression of RIG-I, and knockdown of RIG-I inhibited the induction of CXCL10 in HuCCT1 cells transfected with poly（I:C）. Conclusion: These results suggest that RIG-I-CXCL10 cascade may be involved in the etiology of human BA.

Published
2019

42. Prediction of genetic risk for dyslipidemia

Author

Yamada, Yoshiji, Matsuo, Hitoshi, Warita, Shunichiro, Watanabe, Sachiro, Kato, Kimihiko, Oguri, Mitsutoshi, Yokoi, Kiyoshi, Metoki, Norifumi, Yoshida, Hidemi, Satoh, Kei, Ichihara, Sahoko, Aoyagi, Yukitoshi, Yasunaga, Akitomo, Park, Hyuntae, Tanaka, Masashi, and Nozawa, Yoshinori

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results